Monday 10th of November at the Medicon Valley Alliance Annual Summit, we will present and discuss the key conclusions and take-home messages from this year´s State of Medicon Valley analysis.
“If Europe wants to compete globally, it must build an investor climate that allows biotech and medtech companies not just to start, but to scale. Within the EU, Medicon Valley stands out as one of the strongest and most vibrant life science hubs — yet the financing gap remains clear. Between 2019 and 2025, the Golden Triangle outperformed Flanders, BioValley, BioM and Medicon Valley combined, which is why we need to embrace the UK and create a truly European cluster eco-system that is stronger than the sum of its parts. Europe has the talent and infrastructure — now we need the collaboration, capital and courage to match.” Says MVA CEO Anette Steenberg.
We hope you will take the time to dive into the facts and figures from the various clusters and the identified strategic opportunities for increased collaboration, which can both help point Europe in the right direction and highlight next steps and – hopefully – strengthen EU – UK collaboration ensuring that Europe as such optimize the likelihood of success and mange to bounce back and recreate an innovative life science region stronger than the sum of its constituent parts.
Life Science Sweden just published some of the key findings in their Monday article “Medicon Valley is in the European Champions league when it comes to clinical trials” (in Swedish)